Victory Capital Management Inc. raised its position in DocGo Inc. (NASDAQ:DCGO - Free Report) by 546.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 372,487 shares of the company's stock after acquiring an additional 314,838 shares during the quarter. Victory Capital Management Inc. owned 0.37% of DocGo worth $983,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. Isthmus Partners LLC grew its position in DocGo by 2.3% in the first quarter. Isthmus Partners LLC now owns 638,400 shares of the company's stock valued at $1,685,000 after acquiring an additional 14,472 shares in the last quarter. Diversify Wealth Management LLC acquired a new stake in DocGo in the first quarter valued at approximately $223,000. Bank of New York Mellon Corp boosted its stake in shares of DocGo by 8.1% during the 1st quarter. Bank of New York Mellon Corp now owns 365,468 shares of the company's stock valued at $965,000 after buying an additional 27,309 shares during the last quarter. P.A.W. Capital Corp boosted its stake in shares of DocGo by 25.0% during the 1st quarter. P.A.W. Capital Corp now owns 2,000,000 shares of the company's stock valued at $5,280,000 after buying an additional 400,000 shares during the last quarter. Finally, Ritholtz Wealth Management purchased a new position in shares of DocGo during the 1st quarter valued at approximately $316,000. Institutional investors and hedge funds own 56.44% of the company's stock.
DocGo Price Performance
DCGO traded down $0.03 during trading hours on Friday, hitting $1.33. 568,763 shares of the stock were exchanged, compared to its average volume of 459,240. The stock has a 50-day simple moving average of $1.50 and a 200-day simple moving average of $2.61. DocGo Inc. has a 12 month low of $1.23 and a 12 month high of $5.68. The stock has a market cap of $135.64 million, a price-to-earnings ratio of -66.50 and a beta of 0.97.
DocGo (NASDAQ:DCGO - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.08). DocGo had a positive return on equity of 2.52% and a negative net margin of 0.12%. The firm had revenue of $96.03 million for the quarter, compared to the consensus estimate of $104.25 million. Sell-side analysts expect that DocGo Inc. will post 0.25 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms have recently commented on DCGO. Canaccord Genuity Group reiterated a "hold" rating and set a $1.45 target price (down from $5.00) on shares of DocGo in a research note on Monday, May 12th. Needham & Company LLC reduced their target price on DocGo from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, BTIG Research cut DocGo from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $3.56.
Check Out Our Latest Analysis on DocGo
DocGo Profile
(
Free Report)
DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.
Featured Articles

Before you consider DocGo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.
While DocGo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.